SCHEMBL1012764

SCHEMBL1012764

COC(=O)C1C(=O)C(C(=O)OC)C2CCC1N2C(=O)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
CYP1A2 P05177 1/20 0.49
HIF1A Q16665 1/20 0.49
HTT P42858 2/20 0.48
MITF O75030 1/20 0.48
MAPT P10636 1/20 0.48
AGTR2 P50052 4/20 0.47
PSEN1 P49768 1/20 0.47
PSEN2 P49810 1/20 0.47
APH1B Q8WW43 1/20 0.47
NCSTN Q92542 1/20 0.47
APH1A Q96BI3 1/20 0.47
PSENEN Q9NZ42 1/20 0.47
CPB1 P15086 1/20 0.46
CYP2C19 P33261 1/20 0.45
FKBP1A P62942 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1012557 0.89 HTR2C (0.51) HTR2CSMN1; SMN2NPC1RAB9AAGTR2
SCHEMBL7652421 0.87 SMN1; SMN2 (0.55) HTR2CSMN1; SMN2NPC1RAB9AAGTR2
SCHEMBL29440106 0.83 HTR2C (0.51) HTR2CSMN1; SMN2NPC1RAB9AHTT
SCHEMBL29440077 0.83 HTR2C (0.51) HTR2CSMN1; SMN2NPC1RAB9AHTT
SCHEMBL9546447 0.81 HTR2C (0.57) HTR2CSMN1; SMN2NPC1RAB9ACYP1A2
SCHEMBL1766231 0.79 HTR2C (0.60) HTR2CSMN1; SMN2NPC1RAB9AAGTR2
SCHEMBL1011983 0.79 SLC6A4 (0.54) SMN1; SMN2CYP1A2HIF1AMAPTFKBP1A
SCHEMBL29440040 0.78 HTR2C (0.48) HTR2CSMN1; SMN2NPC1RAB9AHTT
SCHEMBL29440096 0.78 HTR2C (0.48) HTR2CSMN1; SMN2NPC1RAB9AHTT
SCHEMBL29440064 0.78 HTR2C (0.48) HTR2CSMN1; SMN2NPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1118674-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE NIHON MEDIPHYSICS CO LTD (JP) 2011-01-05 EP disclosed
US-20030065183-A1 Process for producing optically active tropinonemonocarboxylic acid ester derivative NIHON MEDI-PHYSICS CO., LTD. 2003-04-03 US disclosed
US-6486323-B1 Process for producing optically active tropinonemonocarboxylic acid derivative NIHON MEDI-PHYSICS CO., LTD. (JP) 2002-11-26 US disclosed
EP-1118674-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE Nihon Medi-Physics Co., Ltd. (JP) 2001-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065183-A1 Process for producing optically active tropinonemonocarboxylic acid ester derivative CES2, FTO, HAAO HTR2C 439/4885SMN1; SMN2 3466/4885NPC1 4594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.